Natera Amends Illumina Supply Agreement in Q2 Filing
The genetic testing company disclosed a fourth amendment to its longstanding supply agreement with sequencing giant Illumina, modifying pricing terms for NIPT testing.
Supply Agreement Modifications
Natera, Inc. disclosed a fourth amendment to its supply agreement with Illumina, Inc., originally executed in August 2013, according to the company's quarterly filing. The amendment, effective as of the date signed, modifies key provisions related to the company's non-invasive prenatal testing (NIPT) business (10-Q filing, 2026-08-07).
The amended agreement updates the definition of "Fetal Chromosomal Abnormalities" and revises Section 6(a) concerning NIPT test fees, though the specific commercial terms remain confidential and were redacted from the public filing. The original supply agreement has been previously amended three times since its 2013 inception, with modifications in September 2014, September 2015, and June 2016.
Strategic Dependency on Illumina
The filing underscores Natera's continued reliance on Illumina as a supplier of sequencing instruments and materials, a relationship that has spanned more than a decade. The company's forward-looking statements indicate that "a significant portion" of revenues will continue to derive from its Panorama NIPT test, along with its Signatera oncology test and Horizon carrier screening product for the foreseeable future (10-Q filing, 2026-08-07).
Natera acknowledged in its risk factors that it relies "on a limited number of suppliers, including sole source suppliers, which may impact our ability to maintain a continued supply of laboratory instruments and materials and to run our tests" (10-Q filing, 2026-08-07).
Regulatory Certifications
The filing included standard Sarbanes-Oxley certifications from Chief Executive Officer Steve Chapman and Chief Financial Officer Michael Brophy for the quarter ended June 30, 2026. Both executives certified that the quarterly report complies with Securities Exchange Act requirements and that the financial information "fairly presents, in all material respects, the financial condition and results of operations of the Company" (10-Q filing, 2026-08-07).
Forward-Looking Outlook
Natera's management discussion highlighted several strategic priorities, including expectations to "successfully develop and commercialize, or enhance" its products and to expand "third-party payer coverage of, and reimbursement for" its tests (10-Q filing, 2026-08-07).
The company specifically referenced its Single nucleotide polymorphism-based Microdeletion and Aneuploidy RegisTry (SMART) Study, expressing expectations that results "may support broader use of and reimbursement for the use of Panorama for microdeletions" (10-Q filing, 2026-08-07).
Additionally, the filing mentioned ongoing integration efforts related to the company's acquisition of Foresight Diagnostics, Inc., though no financial details of this integration were provided in the excerpted portions.
Market Context
According to MarginX data, Natera maintains a market capitalization of approximately $46 billion, with shares last closing at $322.10. Recent insider activity shows sales by Sheena Jonathan totaling 1,700 shares across three transactions. The company is expected to report Q3 2026 results on November 6, 2026.
This article was generated by MarginX from the 10-Q filing on 2026-08-07. It is not investment advice.